Jakub Závada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7086381/publications.pdf

Version: 2024-02-01

331670 175258 2,798 65 21 52 h-index citations g-index papers 69 69 69 3935 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76, 29-42.	0.9	1,096
2	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases, 2020, 79, 31-38.	0.9	225
3	A comparison of three methods to estimate baseline creatinine for RIFLE classification. Nephrology Dialysis Transplantation, 2010, 25, 3911-3918.	0.7	206
4	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, $2017, 76, 386-391$.	0.9	150
5	Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus, 2010, 19, 1281-1289.	1.6	111
6	EQ-5D in Central and Eastern Europe: 2000–2015. Quality of Life Research, 2016, 25, 2693-2710.	3.1	103
7	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.9	77
8	Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology, 2017, 56, 1982-1992.	1.9	62
9	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over $1\hat{a}\in$ year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 96-102.	0.9	61
10	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 252.	3.5	60
11	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.9	47
12	Seroprevalence and specificity of NMO-lgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology International, 2013, 33, 259-263.	3.0	36
13	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	3.8	33
14	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017, 12, e0183420.	2.5	32
15	Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus, 2014, 23, 69-74.	1.6	28
16	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
17	Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up. Archives of Medical Research, 2009, 40, 276-284.	3.3	25
18	Novel dysfunctional variant in <i>ABCG2</i> as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. Rheumatology, 2016, 55, 191-194.	1.9	24

#	Article	IF	CITATIONS
19	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clinical Rheumatology, 2018, 37, 2055-2062.	2.2	23
20	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International, 2019, 39, 469-478.	3.0	23
21	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology, 2015, 54, 1074-1079.	1.9	22
22	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research and Therapy, 2020, 22, 97.	3.5	22
23	Circulating Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis. Kidney and Blood Pressure Research, 2008, 31, 247-254.	2.0	21
24	The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Annals of the Rheumatic Diseases, 2014, 73, 252-255.	0.9	21
25	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371.	3.5	20
26	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. Kardiologia Polska, 2018, 76, 860-870.	0.6	19
27	Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2009, 48, 1197-1201.	1.9	18
28	Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Annals of the Rheumatic Diseases, 2014, 73, 628-628.	0.9	18
29	The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies. JMIR Research Protocols, 2018, 7, e165.	1.0	16
30	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study. Arthritis Research and Therapy, 2017, 19, 5.	3.5	15
31	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. Arthritis Research and Therapy, 2015, 17, 341.	3.5	14
32	Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3Âmonths of treatment with TNF inhibitors. Rheumatology International, 2019, 39, 1749-1757.	3.0	14
33	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS ONE, 2016, 11, e0165498.	2.5	14
34	Rapid and reliable HILIC-MS/MS method for monitoring allantoin as a biomarker of oxidative stress. Analytical Biochemistry, 2020, 589, 113509.	2.4	13
35	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers, 2015, 20, 47-51.	1.9	12
36	<i>Mycobacterium marinum</i> Epididymoorchitis: Case Report and Literature Review. Urologia Internationalis, 2011, 87, 120-124.	1.3	10

#	Article	IF	CITATIONS
37	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. Rheumatology International, 2017, 37, 1957-1977.	3.0	9
38	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. European Journal of Health Economics, 2019, 20, 109-117.	2.8	8
39	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clinical and Experimental Rheumatology, 2019, 37, 342-343.	0.8	8
40	SAT0532â€Updated Eular Evidence-Based Recommendations for the Diagnosis of Gout. Annals of the Rheumatic Diseases, 2014, 73, 783.3-784.	0.9	7
41	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). Journal of Rheumatology, 2020, 47, 658-667.	2.0	7
42	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. Journal of Rheumatology, 2021, 48, 48-57.	2.0	7
43	European bio-naà ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7
44	Two familial cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rheumatology, 2006, 45, 356-357.	1.9	6
45	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Expert Opinion on Biological Therapy, 2020, 20, 183-192.	3.1	5
46	Switching first-line targeted therapy after not reaching low disease activity within $6\hat{A}$ months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. Arthritis Research and Therapy, 2021, 23, 11.	3.5	5
47	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. Rheumatology International, 2022, 42, 803-814.	3.0	3
48	SAT0531â€Updated Eular Evidence-Based Recommendations for the Management of Gout. Annals of the Rheumatic Diseases, 2014, 73, 783.2-783.	0.9	2
49	Patients with REM sleep behavior disorder have higher serum levels of allantoin. Parkinsonism and Related Disorders, 2021, 90, 38-43.	2.2	2
50	A10.3â€Arthritis in Patients with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2013, 72, A72.2-A72.	0.9	1
51	SATO349â€A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 719.1-719.	0.9	1
52	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.8	1
53	Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A15.2-A15.	0.9	0
54	THU0168â€Monotherapy with Biological Disease-Modifying Anti-Rheumatic Drugs-Data from the Czech Registry Attra:. Annals of the Rheumatic Diseases, 2014, 73, 238.2-238.	0.9	0

#	Article	IF	CITATIONS
55	SAT0205â€Potential of US 7 Score in Evaluating of Disease Activity of Patients with Rheumatoid Arthritis in the State of Remission. Annals of the Rheumatic Diseases, 2014, 73, 664.1-664.	0.9	0
56	SAT0188â€Serum Calprotectin (S100A8/9) Correlates with Clinical and Ultrasound Outcomes in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 658.1-658.	0.9	0
57	A2.5â€Novel dysfunctional variant in ABCG2 gene is a cause of primary hyperuricemia and gout: biochemical, molecular genetic and functional analysis. Annals of the Rheumatic Diseases, 2015, 74, A17.2-A17.	0.9	O
58	AB0952â€Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1227.1-1227.	0.9	0
59	A6.18â€Analysis of <i>ABCG2</i> gene in primary hyperuricemia and gout. Annals of the Rheumatic Diseases, 2016, 75, A55.1-A55.	0.9	O
60	FRIO544â€Impact of Education in Musculoskeletal Ultrasonography: Good To Excellent Reliability Results in Modified US7 Scoring System after One Year of Continuing Education since Basic or Intermediate Level of Training. Annals of the Rheumatic Diseases, 2016, 75, 637.1-637.	0.9	0
61	FRI0532â€Association between The 7-Joint Ultrasound Score (US7S) and Physical Function in Rheumatoid Arthritis: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 632.1-632.	0.9	0
62	05.04â€Functional polymorphisms of the abcg2 gene in primary gout. , 2017, , .		0
63	AB0872â€OXIDATIVE STRESS MARKER ALLANTOIN IS NOT ASSOCIATED WITH THE CHANGE OF SERUM URIC A LEVEL IN PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES AFTER ABROGATION OF SYSTEMIC INFLAMMATION BY TNF INHIBITION., 2019,,.	CID	O
64	FRIO107â€THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
65	OUP accepted manuscript. Rheumatology, 2021, , .	1.9	0